Generic drug
Acetaminophen / codeine price, strengths & recalls
Pharmacies pay $7.41 for 30 tablets of Acetaminophen / codeine 300 mg / 30 mg tablet this week, and from $7.41 to $55.44 across its 4 priced strengths and forms. 22 manufacturers make it. It has 5 recalls on record, none ongoing. Its official label last changed on August 19, 2025.
Generic- Fair cash price
- $19.02
- Strengths
- 4
- Makers
- 22
- Updated
- Nov 11
Acetaminophen / codeine price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 24 mg/mL / 2.4 mg/mL oral solution | $0.4699 | $55.44 / 118 mL |
| 300 mg / 15 mg tablet | $0.2661 | $7.98 / 30 tablets |
| 300 mg / 30 mg tablet | $0.2469 | $7.41 / 30 tablets |
| 300 mg / 60 mg tablet | $0.3903 | $11.71 / 30 tablets |
The lowest cost per tablet is 300 mg / 30 mg tablet at $0.2469. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Acetaminophen / codeine
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
BOXED WARNING
WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; HEPATOTOXICITY; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Addiction, Abuse, and Misuse
Acetaminophen and codeine phosphate tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing acetaminophen and codeine phosphate tablets, and monitor all patients regularly for the development of these behaviors and conditions (see
WARNINGS).
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS):
To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products [see
Warnings]. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to
• complete a REMS-compliant education program,
• counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products,
• emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and
• consider other tools to improve patient, household, and community safety.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of acetaminophen and codeine phosphate tablets. Monitor for respiratory depression, especially during initiation of acetaminophen and codeine phosphate tablets or following a dose increase (see
WARNINGS).
Accidental Ingestion
Accidental ingestion of acetaminophen and codeine phosphate tablets, especially by children, can result in a fatal overdose of acetaminophen and codeine phosphate tablets (see
WARNINGS).
Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children
Life-threatening respiratory depression and death have occurred in children who received codeine. Most of the reported cases occurred following tonsillectomy and/or adenoidectomy and many of the children had evidence of being ultra-rapid metabolizers of codeine due to a cytochrome P450 (CYP) 2D6 polymorphism (see
WARNINGS,
PRECAUTIONS; Information for Patients/Caregivers, Nursing Mothers). Acetaminophen and codeine phosphate tablets is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (see
CONTRAINDICATIONS). Avoid the use of acetaminophen and codeine phosphate tablets in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine (see
WARNINGS,
PRECAUTIONS).
Neonatal Opioid Withdrawal Syndrome
Prolonged use of acetaminophen and codeine phosphate tablets during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available (see
WARNINGS,
PRECAUTIONS).
Interactions with Drugs Affecting Cytochrome P450 Isoenzymes
The effects of concomitant use or discontinuation of CYP3A4 inducers, CYP3A4 inhibitors, or CYP2D6 inhibitors with codeine are complex. Use of CYP3A4 inducers, CYP3A4 inhibitors, or CYP2D6 inhibitors with acetaminophen and codeine phosphate tablets requires careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine (see
WARNINGS,
PRECAUTIONS:
DRUG INTERACTIONS).
Hepatotoxicity
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product (see
WARNINGS).
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death (see
WARNINGS,
Drug Interactions).
• Reserve concomitant prescribing of acetaminophen and codeine phosphate tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
• Limit dosages and durations to the minimum required.
•
Follow patients for signs and symptoms of respiratory depression and sedation.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 9 approved generic applications on the market
Acetaminophen / codeine questions
How much does acetaminophen / codeine cost without insurance?
Pharmacies pay about $7.41 for 30 tablets of acetaminophen / codeine 300 mg / 30 mg tablet ($0.2469 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $19.02. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is acetaminophen / codeine in shortage?
No shortage is reported for acetaminophen / codeine right now. We check the national shortage list every day.
Has acetaminophen / codeine been recalled?
5 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the acetaminophen / codeine label last change?
The official label was last updated on August 19, 2025 (version 2). See what changed.
Talk about acetaminophen / codeine
No comments yet. Questions, tips, what worked for you - start the conversation.